| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/05/2003 | CN1395613A 抗微生物组合物 The antimicrobial composition |
| 02/05/2003 | CN1395566A Corticotropin releasing factor antagonists |
| 02/05/2003 | CN1395560A Glyburide composition |
| 02/05/2003 | CN1394602A Benzoic acid substituted benzopyran fro curing atheroscleorsis |
| 02/05/2003 | CN1100564C Medicine for treating HIV infection, its composition and its use |
| 02/05/2003 | CN1100537C Agonists and antagonist for nicotinic acetylcholine receptors of insects to control endoparasites |
| 02/04/2003 | US6515197 Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide |
| 02/04/2003 | US6515119 Use of S-ydcB and B-ydcB, essential bacterial genes |
| 02/04/2003 | US6515117 C-aryl glucoside SGLT2 inhibitors and method |
| 02/04/2003 | US6515028 Glucamine compounds for treating hepatitis virus infections |
| 02/04/2003 | US6515016 Treating or preventing multiple sclerosis, by administering an antimicrotubule agent; treating various other inflammatory diseases |
| 02/04/2003 | US6515007 Methods for managing scalp conditions |
| 02/04/2003 | US6515004 Useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease |
| 02/04/2003 | US6514999 A substance which increases Dopamine concentration in the synaptic cleft of the neurons of the brain, in combination with an effective amount of a local anesthetic of the anilide group or derivatives thereof |
| 02/04/2003 | US6514986 Chiral fluoroquinolone arginine salt forms |
| 02/04/2003 | US6514984 Human non-pancreatic secretory phospholipase A2 inhibitors |
| 02/04/2003 | US6514980 Nucleoside analogs in combination therapy of herpes simplex infections |
| 02/04/2003 | US6514973 Treatment of transmethylation disorders comprising one or more compounds selected from phosphatidyl serines, methyl transporters, and methyl and methylene donors with exipient |
| 02/04/2003 | US6514955 An agent in an amount effective to cause blood glutathione levels to increase, antioxidants at a dose higher than the recommended daily minimum requirement; and nuclear factor kappa B (NFKB) induction inhibitor |
| 02/04/2003 | US6514949 Administering A2A adenosine agonist in combination with an effective amount of a Type IV phosphodiesterase inhibitor for treatment of inflammation caused by an ischemia/reperfusion injury |
| 02/04/2003 | US6514948 Method for enhancing an immune response |
| 02/04/2003 | US6514934 For treating sexual dysfunctions in males and females |
| 02/04/2003 | US6514761 Methods of using BCL-2 for the therapeutic treatment and prevention of diseases |
| 02/04/2003 | US6514752 Homologous recombination for universal donor cells and chimeric mammalian hosts |
| 02/04/2003 | US6514738 Given amino acid sequence; microtubular depolymerization activity in presence of ATP; can be used in diagnosis and treatment of cancer, neurological and vesicular transport disorders. |
| 02/04/2003 | US6514726 Aspergillus fumigatus acetyl coenzyme-A carboxylase genes and polypeptides and uses thereof |
| 02/04/2003 | US6514696 Detection thereof; Using polynucleotide that hybridizes to given nucleotide sequence; Cancer |
| 02/04/2003 | US6514686 Alzheimer's disease |
| 02/04/2003 | US6514537 Citric acid, magnesium hydroxide, water |
| 02/04/2003 | US6514536 Drug preparations for treating sexual dysfunction |
| 02/04/2003 | US6514534 Methods for forming regional tissue adherent barriers and drug delivery systems |
| 02/04/2003 | US6514516 Local anesthetic and a biocompatible controlled release material consisting of polyanhydrides, copolymers of lactic acid and glycolic acid, poly(lactic) acid, poly(glycolic) acid, polyesters, polyorthoesters, proteins, polysaccharides |
| 02/04/2003 | US6514513 Costimulatory blockade and mixed chimerism in transplantation |
| 02/04/2003 | US6514506 Melanin-degrading enzyme extract; twice as effective as kojic acid |
| 02/04/2003 | US6514497 Inhibition of LERK-2-mediated cell adhesion |
| 02/04/2003 | CA2362539C Fluorocarbon aerosol medicaments |
| 02/03/2003 | WO2002016548A2 Novel g protein-coupled receptor |
| 02/03/2003 | CA2418130A1 Novel g protein-coupled receptor |
| 02/03/2003 | CA2391627A1 Ribosome structure and protein synthesis inhibitors |
| 01/31/2003 | WO2002012338A2 Screening method |
| 01/31/2003 | WO2002007761A1 Inhibiting hepatitis c virus processing and replication |
| 01/31/2003 | CA2417972A1 Screening method |
| 01/31/2003 | CA2416603A1 Inhibiting hepatitis c virus processing and replication |
| 01/30/2003 | WO2003008635A2 η-SECRETASE IN VITRO SCREENING ASSAY |
| 01/30/2003 | WO2003008633A1 Screening method using fish embryo |
| 01/30/2003 | WO2003008630A2 Methods of profiling gene expression, protein or metabolite levels |
| 01/30/2003 | WO2003008581A1 p53-DEPENDENT APOPTOSIS-INDUCING PROTEIN AND METHOD OF SCREENING APOPTOSIS REGULATOR |
| 01/30/2003 | WO2003008579A2 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby |
| 01/30/2003 | WO2003008578A2 Reagents and methods for identifying gene targets for treating cancer |
| 01/30/2003 | WO2003008574A1 Mutations in ion channels |
| 01/30/2003 | WO2003008560A2 A novel g protein-coupled receptor, gave8 |
| 01/30/2003 | WO2003008548A2 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 01/30/2003 | WO2003008452A2 Bispecific monoclonal antibodies to il-12 and il-18 receptors |
| 01/30/2003 | WO2003008449A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 01/30/2003 | WO2003008448A2 Novel human proton-gated channels |
| 01/30/2003 | WO2003008387A1 Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
| 01/30/2003 | WO2003008365A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | WO2003008010A1 Stents with vitronectin receptor antagonists against restenosis |
| 01/30/2003 | WO2003007995A2 Pharmaceutical preparations containing ion exchange resins charged with fluoroquinolone |
| 01/30/2003 | WO2003007993A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 01/30/2003 | WO2003007992A1 Remedies for brain ischemic diseases |
| 01/30/2003 | WO2003007976A1 High protein, bowman-birk inhibitor concentrate and process for its manufacture |
| 01/30/2003 | WO2003007967A1 Medical preparation for parenteral injection |
| 01/30/2003 | WO2003007966A1 Active substance combination for medicamentous therapy of nicotine dependency |
| 01/30/2003 | WO2003007962A1 A combination therapy for the treatment of heart failure |
| 01/30/2003 | WO2003007955A2 Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| 01/30/2003 | WO2003007951A1 A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| 01/30/2003 | WO2003007949A1 Bridged piperidine derivatives as melanocortin receptor agonists |
| 01/30/2003 | WO2003007945A1 Viral polymerase inhibitors |
| 01/30/2003 | WO2003007932A1 Body fat level controllers |
| 01/30/2003 | WO2003007931A1 Sulfonamide derivatives |
| 01/30/2003 | WO2003007929A1 Amine compounds and inhibiting neurotransmitter reuptake |
| 01/30/2003 | WO2003007924A2 Combinations comprising epothilones and pharmaceutical uses thereof |
| 01/30/2003 | WO2003007917A1 Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| 01/30/2003 | WO2003007916A1 Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| 01/30/2003 | WO2003007889A2 Therapeutic agents comprising pro-apoptotic proteins |
| 01/30/2003 | WO2003007880A2 Inhibition of behab cleavage and primary central nervous system (cns) tumors |
| 01/30/2003 | WO2003007800A2 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| 01/30/2003 | WO2003007782A2 Biodegradable injectable implants and related methods of manufacture and use |
| 01/30/2003 | WO2003007686A2 Use of copper chelators to inhibit the inactivation of protein c |
| 01/30/2003 | WO2002088079A3 Dual inhibitors of pde 7 and pde 4 |
| 01/30/2003 | WO2002087554A3 Ef-tu binding agent as antibacterial agent |
| 01/30/2003 | WO2002072078A9 Use of sugar phosphates, amino acids, amino acid analogs, e.g. carbomethoxypropionyl cyanide for reducing weight or diabetes complications |
| 01/30/2003 | WO2002069945A3 Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors |
| 01/30/2003 | WO2002066002A3 Pharmaceutical formulation |
| 01/30/2003 | WO2002064160A8 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 01/30/2003 | WO2002055136A3 Intrasvascular drug delivery device and use therefor |
| 01/30/2003 | WO2002053097A3 Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| 01/30/2003 | WO2002053096A3 Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins |
| 01/30/2003 | WO2002051435A3 New therapeutic uses of smr1 peptides |
| 01/30/2003 | WO2002051355A3 Acetyl-coenzyme a carboxylase 2 as a target in fat regulation and insulin action |
| 01/30/2003 | WO2002043666A3 Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin c or vitamin e for preventing or inhibiting loss of cognitive function |
| 01/30/2003 | WO2002038158A8 Improved treatment |
| 01/30/2003 | WO2002034243A3 Method for the treatment of neurological and neuropsychological disorders |
| 01/30/2003 | WO2002034242A3 Method for the treatment of neurological and neuropsychological disorders |
| 01/30/2003 | WO2002026988A3 Human drug metabolizing enzymes |
| 01/30/2003 | WO2002020763A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 01/30/2003 | WO2002018583A3 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 01/30/2003 | WO2002017858A3 Role of fosb in bone formation |
| 01/30/2003 | WO2002016567A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |